Do you feel Wegovy working straight away, or does it take time?

Wegovy (semaglutide) starts at 0.25 mg, a tolerability dose whose job is to let your body adjust, not to produce immediate weight loss.
The most noticeable appetite changes for many people arrive once the dose steps up, typically from week five onwards.
Side effects like nausea are often most noticeable in the first few weeks and tend to ease as your body settles in.
Clinical trial data from the STEP 1 study showed around 15% average weight reduction over 68 weeks, meaningful results build over months, not days.

Most people do not feel Wegovy right away in any dramatic sense. The medicine begins interacting with GLP-1 receptors from the first dose, but the effects on appetite and fullness tend to build gradually over several weeks as the dose increases. That said, some people notice subtle changes — a slightly earlier sense of fullness, or less interest in snacking — within the first week or two. These are prescription-only medicines, and a prescriber assesses whether Wegovy is right for you before any treatment begins.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What actually happens in your body during the first weeks on Wegovy

Week one to four: the adjustment phase

The first pen of Wegovy contains 0.25 mg semaglutide. This starting dose exists specifically to give your system time to adapt, it is not meant to suppress appetite strongly or shift the number on the scale. Think of it as the settling-in period.

That does not mean nothing is happening. Semaglutide slows the rate at which food leaves your stomach, and it acts on areas of the brain involved in hunger signalling. Some people report a quieter appetite even at this stage. Others feel almost nothing different, and that is entirely normal too, as our collection of Wegovy forum posts and user reviews reflects across a wide range of experiences.

The most common experience in week one is mild nausea, particularly after eating. This is the side effect people hear about most, and for good reason, it affects a meaningful proportion of users early on. It usually improves within days to a couple of weeks. Eating smaller portions, avoiding greasy food and staying well hydrated all help. If you find yourself wondering how people generally feel on Wegovy day to day, the honest answer is: quite varied at this stage, and settling.

The NHS notes that nausea, vomiting, diarrhoea and constipation are the most frequently reported early effects of semaglutide, and they are covered in detail on the NHS semaglutide medicines page.

Weeks five to sixteen: when most people start to feel the difference

After four weeks at 0.25 mg, the prescriber's titration schedule moves the dose up, first to 0.5 mg, then to 1.0 mg, continuing roughly every four weeks toward the 2.4 mg maintenance dose. Each step can bring a more noticeable shift in appetite.

This is the phase where many people describe a genuine change in their relationship with food. Meals that used to feel easy to finish become harder to get through. Cravings for high-calorie foods can quieten. The urge to snack between meals fades for some people almost completely.

A practical checking habit worth building: before each meal during this phase, pause for thirty seconds and honestly rate your hunger on a scale of one to ten. People often find, after a few weeks, that they are starting meals at a four or five rather than an eight, and that small shift adds up over months. If you are curious about whether Wegovy works right away or needs time to build up before the effects become noticeable, the answer depends on which effects you are tracking and at what dose.

Weight loss during this middle phase is usually gradual, half a kilogram to a kilogram per week on a reduced-calorie diet is a realistic range for many, though results vary considerably. The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks and recorded around 15% average body-weight reduction at the 2.4 mg maintenance dose. That trajectory is a marathon, not a sprint.

From maintenance dose onwards: what longer-term use feels like

Once someone reaches and stabilises at the 2.4 mg weekly dose, appetite suppression tends to be at its most consistent. Many people at this stage describe food noise (the background mental chatter about eating) as significantly quieter than before treatment.

It is worth knowing that the effect can plateau. If weight loss slows or stops, that is a signal to review the whole picture: calorie intake, protein adequacy, activity levels, sleep, stress. The medicine works alongside lifestyle changes, not instead of them. The Wegovy overview page covers the evidence and what the treatment involves in more detail.

A newer 7.2 mg maintenance dose has also been approved by the MHRA (the dedicated single-dose pen was authorised on 14 April 2026) for adults with a BMI of 30 or above. Trial data at this higher dose reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide results. Whether this dose is appropriate is always a clinical decision made with your prescriber.

If you are weighing up your options, the eligibility and suitability page is a good place to think through whether Wegovy fits your circumstances. And for a broader look at weight-loss treatments available through a GPhC-registered pharmacy, starting a free consultation is the next step.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions